Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimal dose regimen in this […]
Read More
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
